Evaluation of Hbv-Dna in Patients With Different Serologic Markers

Abstract

In this study, patients infected with HBV with uncharacteristic serologic markers were interpreted and their probable clinical stages were determined. With this purpose, 75 patients were evaluated for HBV-DNA and hepatitis serologic markers. HBV-DNA results were obtained using bDNA-Bayer kits and serologic markers were detected using microparticle enzyme immunoassay (MEIA) kits. From 75 patients, 54 (72%) were HBV-DNA positive, and 35 (64.8%) of them were HBeAg positive. From 21 (28%) patients who are HBV-DNA negative, only 1 (4.8%) patient was HBeAg positive. HBsAg, HBeAg, anti-HBe, anti-HBc IgM and anti-HBc IgG of 46 patients were compared with HBV-DNA results simultaneously and 31 (67.4%) patients were HBV-DNA positive and HBsAg, HBeAg, anti-HBe, anti-HBc IgM, anti-HBc IgG results were positive in 29 (63%), 22 (48%), 7 (15%), 1 (2%), and 29 (63%) patients respectively. In 15 (33%) patients with negative HBV-DNA results, HBsAg in 14 (30%), HBeAg in 1 (2%), anti-HBe in 13 (28%), anti-HBc IgG in 14 (30%) were positive, and none of them were positive for anti-HBc IgM.